These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37655058)

  • 41. Ustekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease.
    Petrov J; Fine S; Alzahrani R; Mohamed G; Al-Bawardy B
    J Clin Gastroenterol; 2024 Feb; ():. PubMed ID: 38300529
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative Effectiveness of Ustekinumab Versus Adalimumab in Induction of Clinical Response and Remission in Crohn's Disease: Experience of a Real-World Cohort at a Tertiary Care Inflammatory Bowel Disease Referral Center.
    Ahmed Z; Venkata K; Zhang N; Malik TA
    Gastroenterology Res; 2019 Oct; 12(5):245-251. PubMed ID: 31636774
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
    Macaluso FS; Fries W; Viola A; Costantino G; Muscianisi M; Cappello M; Guida L; Giuffrida E; Magnano A; Pluchino D; Ferracane C; Magrì G; Di Mitri R; Mocciaro F; Privitera AC; Camilleri S; Garufi S; Renna S; Casà A; Scrivo B; Ventimiglia M; Orlando A
    Expert Opin Biol Ther; 2020 Nov; 20(11):1381-1384. PubMed ID: 32981373
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of ustekinumab, infliximab and combination therapy in moderately to severely active ulcerative colitis - a study protocol of a randomized, multicenter, head-to-head COMBO-UC trial.
    Talar-Wojnarowska R; Fabisiak A; Zatorski H; Płoszka K; Błaziak K; Fendler W; Rydzewska G; Małecka-Wojciesko E; Eder P
    Front Med (Lausanne); 2024; 11():1458998. PubMed ID: 39364021
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual-Targeted Therapy with Upadacitinib and Ustekinumab in Medically Complex Crohn's Disease.
    Miyatani Y; Choi D; Choi NK; Rubin DT
    Dig Dis Sci; 2024 Feb; 69(2):355-359. PubMed ID: 38112840
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Real-World Effectiveness and Safety of Ustekinumab in Elderly Crohn's Disease Patients.
    Garg R; Aggarwal M; Butler R; Achkar JP; Lashner B; Philpott J; Cohen B; Qazi T; Rieder F; Regueiro M; Click B
    Dig Dis Sci; 2022 Jul; 67(7):3138-3147. PubMed ID: 34160735
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn's disease.
    Macaluso FS; Grova M; Saladino M; Cappello M; Demarzo MG; Privitera AC; Giangreco E; Garufi S; Renna S; Casà A; Ventimiglia M; Fries W; Orlando A;
    Dig Liver Dis; 2023 Apr; 55(4):471-477. PubMed ID: 36127230
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness and safety of ustekinumab in bio-naïve Crohn's disease patients: a multicentre observational retrospective study.
    Teresa VD; Rául OM; Marisa I; Claudia HG; Esteban FV; Luigi M; Mª Mar MR; Lilyan KC; Luisa CP; Ángel PD; Raquel VL; Noemí MM; Benito VJ; Marta LS; Beatriz LC; Francisco MG; Pau GÁ; Federico AA
    Therap Adv Gastroenterol; 2023; 16():17562848231153560. PubMed ID: 36777363
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis.
    Uchida G; Nakamura M; Yamamura T; Maeda K; Sawada T; Ishikawa E; Furukawa K; Iida T; Mizutani Y; Yamao K; Ishikawa T; Ishizu Y; Honda T; Ishigami M; Kawashima H
    Inflamm Intest Dis; 2023 Oct; 8(2):60-68. PubMed ID: 37901340
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
    Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
    [TBL] [Abstract][Full Text] [Related]  

  • 51. USTEKINUMAB IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN OBSERVATIONAL STUDY.
    Castro PCS; Magro DO; Nones RB; Furlan TK; Miranda EF; Kotze PG
    Arq Gastroenterol; 2022; 59(4):501-507. PubMed ID: 36515346
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ustekinumab in Crohn's disease: effectiveness and safety in clinical practice.
    Saldaña Dueñas C; Rullán Iriarte M; Elosua González A; Rodríguez Gutiérrez C; Rubio Iturria S; Nantes Castillejo Ó
    Gastroenterol Hepatol; 2020 Nov; 43(9):497-505. PubMed ID: 32703654
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium.
    Johnson AM; Barsky M; Ahmed W; Zullow S; Galati J; Jairath V; Narula N; Peerani F; Click BH; Coburn ES; Dang TT; Gold S; Agrawal M; Garg R; Aggarwal M; Mohammad D; Halloran B; Kochhar GS; Todorowski H; Ud Din NM; Izanec J; Teeple A; Gasink C; Muser E; Ding Z; Swaminath A; Lakhani K; Hogan D; Datta S; Ungaro RC; Boland BS; Bohm M; Fischer M; Sagi S; Afzali A; Ullman T; Lawlor G; Baumgart DC; Chang S; Hudesman D; Lukin D; Scherl EJ; Colombel JF; Sands BE; Siegel CA; Regueiro M; Sandborn WJ; Bruining D; Kane S; Loftus EV; Dulai PS
    Am J Gastroenterol; 2023 Feb; 118(2):317-328. PubMed ID: 36191274
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ustekinumab is associated with superior treatment persistence but not with higher remission rates
    Bacsur P; Matuz M; Resál T; Miheller P; Szamosi T; Schäfer E; Sarlós P; Iliás Á; Szántó K; Rutka M; Bálint A; Milassin Á; Fábián A; Bor R; Szepes Z; Molnár T; Farkas K
    Therap Adv Gastroenterol; 2022; 15():17562848221144349. PubMed ID: 36600684
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study.
    Bar-Gil Shitrit A; Ben-Ya'acov A; Siterman M; Waterman M; Hirsh A; Schwartz D; Zittan E; Adler Y; Koslowsky B; Avni-Biron I; Chowers Y; Ron Y; Israeli E; Ungar B; Yanai H; Maharshak N; Ben-Horin S; Eliakim R; Dotan I; Goldin E; Kopylov U
    United European Gastroenterol J; 2020 May; 8(4):418-424. PubMed ID: 32213026
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
    Adedokun OJ; Xu Z; Gasink C; Jacobstein D; Szapary P; Johanns J; Gao LL; Davis HM; Hanauer SB; Feagan BG; Ghosh S; Sandborn WJ
    Gastroenterology; 2018 May; 154(6):1660-1671. PubMed ID: 29409871
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.
    Liefferinckx C; Verstockt B; Gils A; Noman M; Van Kemseke C; Macken E; De Vos M; Van Moerkercke W; Rahier JF; Bossuyt P; Dutré J; Humblet E; Staessen D; Peeters H; Van Hootegem P; Louis E; Franchimont D; Baert F; Vermeire S;
    J Crohns Colitis; 2019 Oct; 13(11):1401-1409. PubMed ID: 30989232
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness and safety of ustekinumab dose escalation in Crohn's disease: a multicenter observational study.
    Olmedo Martín RV; Vázquez Morón JM; Martín Rodríguez MDM; Lázaro Sáez M; Hernández Martínez Á; Argüelles-Arias F
    Rev Esp Enferm Dig; 2023 Dec; 115(12):686-692. PubMed ID: 37314131
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies.
    Narula N; Aruljothy A; Wong ECL; Homenauth R; Alshahrani AA; Marshall JK; Reinisch W
    United European Gastroenterol J; 2021 Jun; 9(5):581-589. PubMed ID: 34077627
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI).
    Hisamatsu T; Kim HJ; Motoya S; Suzuki Y; Ohnishi Y; Fujii N; Matsushima N; Zheng R; Marano CW
    Intest Res; 2021 Oct; 19(4):386-397. PubMed ID: 33249802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.